MDVN almost always reports AFTER Astellas but this time they are reporting before they are. That's a little interesting, don't you think? The only reason I can figure this might be is because Astellas is reporting end of year results? Not sure though.
I know that founders always feel like they can do everything and that they want to run their own thing and that the big corporations will undermine innovation but I want management to sell this one. They have great products that they can develop even faster with deeper pockets. It also provides a nice ending to those of us who have been holding since the dimebom days.
I say, let the big guys buy them out, ramp more clinical trials to get your product to market faster. If you want to grow something from scratch, go start another one.
Watching this thing has been like watching a pinball machine lately! Up, down, lots of movement all over the place. Seems to me that the next catalyst for this thing will be the ph 3 trial of the drug they bought vs. anything else. Am i missing something or does everyone else feel that way too?